Sarilumab SAR153191 (REGN88)
EFC15160
Phase 3 small_molecule terminated
Quick answer
Sarilumab SAR153191 (REGN88) for Polymyalgia Rheumatica is a Phase 3 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Polymyalgia Rheumatica
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated